Loading clinical trials...
Loading clinical trials...
Phase 1/2, Double-blind, Randomized, Active-controlled First-in-human Clinical Trial to Evaluate the Safety and Immunogenicity of the Chimeric SpiN-Tec MCTI UFMG Vaccine for Covid19
Conditions
Interventions
SpiN-Tec MCTI UFMG
Active Comparator: Covishield® vaccine
+1 more
Locations
1
Brazil
Faculdade de Medicina da UFMG - Unidade de Pesquisa Clínica em Vacinas (UPqVac)
Belo Horizonte, Minas Gerais, Brazil
Start Date
November 23, 2022
Primary Completion Date
May 22, 2023
Completion Date
May 7, 2025
Last Updated
September 15, 2025
NCT07190131
NCT06831786
NCT07190911
NCT07126392
NCT07118917
NCT06776276
Lead Sponsor
Federal University of Minas Gerais
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions